News

60 Degrees Pharmaceuticals Reports Strong Q3 Revenue Growth

60 Degrees Pharmaceuticals Reports Strong Q3 Revenue Growth

Overview of Recent Financial Performance

In a significant update from 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP), the company announced an increase in net product revenue for the third quarter of 2025. The revenue soared to $438 thousand, marking an impressive 223% rise compared to the same time last year. Despite this growth, the company experienced challenges with a gross loss that deepened from $24 thousand to $100 thousand.

Financial Highlights for Q3 2025

During the third quarter of 2025, several key financial metrics highlighted the company's evolving landscape:

  • The volume of ARAKODA® pharmacy deliveries rose by 14%, reflecting a growth from 1,319 boxes in Q3 2024 to 1,505 boxes in Q3 2025.
  • The company faced a significant gross loss of about $100 thousand, attributed primarily to a one-time inventory write-off linked to validation lots that will not meet supply chain acceptance past early 2026. However, new lots with adequate shelf-life are currently in production and are anticipated to integrate into the supply chain soon.
  • Operating expenses reached approximately $2.32 million, an uptick from $2.16 million in the previous year. This increase was significantly influenced by added advertising and promotional expenditures which accounted for $367 thousand.
  • The net loss attributable to common shareholders was approximately $2.44 million, translating to a loss of ($0.66) per share. In the same quarter last year, the loss was roughly $2.27 million, or ($4.65) per share.

Strategic Business Developments

Aside from financial performance, 60 Degrees Pharmaceuticals has made considerable strides in its business initiatives during this quarter:

  • On July 14, the company expressed its intent to pursue a Minor Use Minor Species (MUMS) designation from the FDA to treat acute canine babesiosis following an extensive analysis of their existing data.
  • A nationwide survey involving 6,000 patients was conducted, leading to a determination of the total addressable market (TAM) for Babesiosis treatment, estimated at up to $1.1 billion leading up to patent expiration in 2035.
  • A sponsored research agreement with Tulane University was established on July 17 to explore the efficacy of tafenoquine against Borrelia (Lyme) and Bartonella bacteria.
  • Furthermore, on August 19, a partnership with the Icahn School of Medicine at Mount Sinai was announced, focused on a Phase II clinical study evaluating tafenoquine in treating chronic babesiosis.

About 60 Degrees Pharmaceuticals, Inc.

Founded in 2010, 60 Degrees Pharmaceuticals, Inc. is at the forefront of developing new treatments for vector-borne diseases. The company celebrated the FDA approval of ARAKODA® (tafenoquine) in 2018, which is aimed at the prevention of malaria. Collaborating with esteemed research organizations across the U.S., Australia, and Singapore underscores its commitment to advancing pharmaceutical science. Significant funding support has come from the U.S. Department of Defense alongside private investors such as Knight Therapeutics Inc. The headquarters are located in Washington D.C., with a major subsidiary positioned in Australia.

Frequently Asked Questions

What financial results did 60 Degrees Pharmaceuticals report for Q3 2025?

The company reported a net product revenue increase of 223% year-over-year, amounting to $438 thousand, alongside a gross loss of approximately $100 thousand.

What are the key business developments from 60 Degrees Pharmaceuticals?

The company announced its intention to pursue MUMS designation for canine babesiosis, a significant market analysis indicating a TAM of up to $1.1 billion, and established research partnerships for ongoing clinical studies.

How did operating expenses change in Q3 2025?

Operating expenses increased to around $2.32 million due to a rise in advertising and sales promotion costs compared to the previous year.

What is ARAKODA® and its significance?

ARAKODA® (tafenoquine) is the lead product from 60 Degrees Pharmaceuticals, approved for malaria prevention. It represents a key achievement for the company in developing treatments for vector-borne diseases.

Who should I contact for media and investor inquiries regarding 60 Degrees Pharmaceuticals?

For media inquiries, contact Sheila A. Burke at SheilaBurke-consultant@60degreespharma.com. For investor inquiries, reach Patrick Gaynes at patrickgaynes@60degreespharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 85

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 65

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 38

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 30

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 34

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 68

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 23

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 189

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 67

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Butterfly Network and Rutgers Study Show Impact of POCUS

Updated Category News Views 129

Revolutionizing Hospital Care with POCUS Technology BURLINGTON, Mass. & NEW YORK-- Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company, has launched a significant study in collaboration with Rutgers Robert Wood Johnson Medical School. This research emphasizes the transformative influence of point-of-care ultrasound (POCUS) technology on patient...

Continue Reading
Civista Bancshares Increases Quarterly Dividend to 17 Cents

Updated Category News Views 127

Civista Bancshares Boosts Quarterly Dividend Payments Civista Bancshares, Inc. (NASDAQ: CIVB), the financial cornerstone of Civista Bank, has made a noteworthy announcement regarding its quarterly dividends. The Board of Directors has approved a hike in the dividend to 17 cents per common share. This increment of 1 cent reflects the company's commitment to returning value...

Continue Reading
Argentinians Traveling Abroad for Cheaper Goods and Prices

Updated Category News Views 233

Argentinians Seeking Affordable Goods Abroad Amid rising domestic prices, it seems that many Argentinians are turning their eyes overseas in search of better deals on consumer goods. This trend has become evident as locals prioritize travel to countries like Brazil and Chile, where prices are significantly lower. The ongoing economic situation in Argentina, characterized...

Continue Reading
RomReal's Annual Report Insights and Audit Overview for 2024

Updated Category News Views 229

RomReal's Performance Overview for 2024 RomReal has been navigating a dynamic market landscape, with its annual report revealing insights into the company's financial health and operational resilience. The company has shown remarkable adaptability in the face of fluctuations within the industry, contributing to its performance in the 2024 fiscal year. This overview sheds...

Continue Reading
Microsoft's Flexible Work Policy: A New Era for Employees

Updated Category News Views 303

Microsoft rolled out a major statement back in 2024 that they're not gonna enforce a mandatory return-to-office unless they see productivity tank. Bigwigs at the company made it clear that for now, keeping things flexible is the name of the game. And why wouldn’t it be? With new hires flocking to companies that let them work from home, Microsoft knows they need to play...

Continue Reading